Literature DB >> 17263629

Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor.

Li Huang1, Weihong Lai, Phong Ho, Chin Ho Chen.   

Abstract

Conformational changes in HIV-1 envelope glycoproteins, gp120 and gp41, is a dynamic process essential for HIV-1 entry. Here we show that a small molecule HIV-1 entry inhibitor, IC9564, induces a conformational change in gp120. The conformational change in gp120 is evidenced by a significant increase in the binding of a conformational monoclonal antibody 17b. As a result of the conformational effect, IC9564 significantly enhances the neutralizing activity of 17b. Unlike CD4, IC9564 does not trigger conformational changes in gp41. In fact, IC9564 inhibits CD4-induced conformational changes in gp41. Thus, IC9564 exploits the dynamic nature of gp120 by inducing a nonproductive gp120 conformation that is not able to trigger a conformational change in gp41 for membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263629     DOI: 10.1089/aid.2006.0137

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.

Authors:  Zhao Dang; Keduo Qian; Phong Ho; Lei Zhu; Kuo-Hsiung Lee; Li Huang; Chin-Ho Chen
Journal:  Bioorg Med Chem Lett       Date:  2012-07-03       Impact factor: 2.823

2.  Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.

Authors:  Zhao Dang; Lei Zhu; Weihong Lai; Hal Bogerd; Kuo-Hsiung Lee; Li Huang; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2016-01-09       Impact factor: 4.345

3.  A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.

Authors:  Edward J Murray; Daniel P Leaman; Nishant Pawa; Hannah Perkins; Chris Pickford; Manos Perros; Michael B Zwick; Scott L Butler
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

Review 4.  Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents.

Authors:  Reen-Yen Kuo; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2009-08-13       Impact factor: 13.423

5.  Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

Authors:  Weihong Lai; Li Huang; Phong Ho; Zhijun Li; David Montefiori; Chin-Ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

6.  Structure Optimization of Aloperine Derivatives as HIV-1 Entry Inhibitors.

Authors:  Zhao Dang; Hua Xie; Lei Zhu; Qingye Zhang; Zhijun Li; Li Huang; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2017-10-09       Impact factor: 4.345

Review 7.  HIV entry inhibitors and their potential in HIV therapy.

Authors:  Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2009-03       Impact factor: 12.944

8.  Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.

Authors:  Zhao Dang; Weihong Lai; Keduo Qian; Phong Ho; Kuo-Hsiung Lee; Chin-Ho Chen; Li Huang
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

9.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

Review 10.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.